Cel Sci Corporation (CVM)

[Fosco1]

Rogue2, scarce poster but valuable insight

Thanks

I have come to the point that I have little doubt on the fact that SoC survival for the actual trial population is pretty under 60% at Y3 and 50% at Y5 (and I made various cross checked with other countries figures such as Canada, UK, Germany), which bodes pretty well for the success of this trial ... provided that dropouts are contained under a reasonable number.

Like I wrote in the last two post that's my last area of uncertainty, where I am not 99% sure : how many patients does the standard design of the study allow to lose for tracking (meaning losing the capacity to assess if living or dead) to preserve its power ? Is it 144 (928 - 784) or 630 (928-298) or another number ?

Obviously, IDMC would not complain about dropouts and study power as long dropouts have not reached this number. "There are likely not such many dropouts because IDMC didn't say anything " sentence as reported from M. De Windt various times could be true if this number is 144 (dropouts containment by 15.5% max).

Depending on the answer, we could be in full confidence of success right now or just only "reasonably" confident,

Fosco